Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck, which previously predicted 2024 sales between 20.7 billion ... continues to regain ground from a slump after the end ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Further evidence from Pfizer that it is no longer dependent on income from COVID-19 products could be a catalyst for the ...

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...